Physician profile
Reena Thomas
NPI 1649270695
$1,839.92
in general payments reported to CMS, 2019-2025
25 companies · $395 in 2025
The $395 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $153 · 2020: $104 · 2021: $321 · 2022: $348 · 2023: $254 · 2024: $264 · 2025: $395.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $914.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $913.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $555.60 | 2020-2025 | Qulipta, Ubrelvy |
| Ucb, INC. | $332.08 | 2019-2025 | Briviact |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $246.53 | 2019-2023 | Xifaxan |
| Lundbeck LLC | $85.93 | 2022-2024 | Vyepti |
| Biohaven Pharmaceuticals, INC. | $71.60 | 2021 | |
| Vifor Pharma, INC. | $65.26 | 2019 | |
| Eisai INC. | $61.07 | 2022-2023 | |
| Abbott Laboratories | $43.63 | 2022-2025 | Infinity |
| Lilly USA, LLC | $39.09 | 2025 | Kisunla, Amyvid |
| Argenx US, INC. | $36.76 | 2022-2023 | Vyvgart |
| Aimmune Therapeutics, INC. | $36.06 | 2024 | |
| Alexion Pharmaceuticals, INC. | $30.13 | 2019 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $27.70 | 2022 | |
| Impel Pharmaceuticals INC. | $24.73 | 2023 | Trudhesa |
| Catalyst Pharmaceuticals, INC. | $22.65 | 2024 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Philips North America LLC | $18.72 | 2024 | (Ck4) Mcot |
| Qol Medical, LLC | $18.12 | 2021 | |
| Sk Life Science, INC. | $18.01 | 2025 | |
| Neurelis, INC. | $16.77 | 2025 | Valtoco |
| Nestle Healthcare Nutrition INC. | $16.54 | 2022 | |
| Globus Medical, INC. | $15.54 | 2025 | Senza |
| Amgen INC. | $15.17 | 2025 | Uplizna |
| Novo Nordisk INC | $14.83 | 2023 | |
| Braintree Laboratories, INC. | $14.11 | 2022 | |
| Shire North American Group INC | $13.29 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Reena Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.